신약임상시험을 위한 표준화된 데이터 수집을 위한 병리학적 반응 평가의 범암통합((PATHdata): 암 면역요법 사회 다기관 재현성 연구 결과

Deutsch 외. (Sun,)은 이 질문을 연구하였다.

www.synapsesocial.com/papers/69a765bfbadf0bb9e87da498 — DOI: https://doi.org/10.1016/j.annonc.2026.01.011

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancer· 2005 · 725 citations
2. End Points and United States Food and Drug Administration Approval of Oncology Drugs· 2003 · 480 citations
3. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy· 2007 · 1,652 citations
4. Excellent Interobserver Agreement on Grading the Extent of Residual Carcinoma After Preoperative Chemoradiation in Esophageal and Esophagogastric Junction Carcinoma: A Reliable Predictor for Patient Outcome· 2006 · 120 citations
5. CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients· 2025 · 3 citations